Zobrazeno 1 - 10
of 188
pro vyhledávání: '"Nava Zisapel"'
Autor:
Yael Mali, Nava Zisapel
Publikováno v:
Neurobiology of Disease, Vol 37, Iss 3, Pp 673-681 (2010)
A gain of interaction of the amyotrophic lateral sclerosis (ALS)-linked G93A-superoxide dismutase-1 (G93A-hSOD1) with cytosolic malate dehydrogenase (cytMDH), a key enzyme in the malate–aspartate shuttle, diverts neurons towards anaerobic metabolis
Externí odkaz:
https://doaj.org/article/b9c21bf4a87b463b816fc63fdae54e24
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e37894 (2012)
The neurexin genes (NRXN1/2/3) encode two families (α and β) of highly polymorphic presynaptic proteins that are involved in excitatory/inhibitory synaptic balance. Recent studies indicate that neuronal activation and memory formation affect NRXN1/
Externí odkaz:
https://doaj.org/article/353c0f2e4a9740d78779b59762ecaabb
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e18579 (2011)
The three neurexins genes (NRXN1/2/3) encode polymorphic synaptic membrane proteins that are involved in cognitive functioning. Neurexins' selectivity of function is presumably conferred through differential use of 2 promoters and 5 alternative splic
Externí odkaz:
https://doaj.org/article/1c054914eda14c6b95fe2ebd68342a08
Publikováno v:
The Journal Of Prevention of Alzheimer's Disease. :1-8
Background: Piromelatine is a novel melatonin MT1/2/3 and serotonin 5-HT-1A/1D receptors agonist developed for mild Alzheimer’s disease (AD). In a randomized, placebo-controlled, dose-ranging study (ReCognition) of piromelatine (5, 20, and 50 mg da
Autor:
Nava Zisapel
Publikováno v:
Expert review of clinical pharmacology. 15(2)
Melatonin preparations are emerging first-line pharmacotherapy for insomnia in children and adolescents with autism spectrum disorder (ASD), but quality, formulation, consistency, dosing, and limited long-term safety data are of concern. The recent a
Autor:
Raun D. Melmed, Robert L. Findling, Carmen M. Schröder, Paul Gringras, Shiri Shahmoon, Nava Zisapel, Athanasios Maras, John Breddy, Beth A. Malow, Tali Nir
Publikováno v:
Journal of Autism and Developmental Disorders
A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2–17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mi
Autor:
Shiri Shahmoon, Tali Nir, Nava Zisapel, Carmen M. Schröder, John Breddy, Robert L. Findling, Athanasios Maras, Beth A. Malow, Paul Gringras
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objective: A recent double-blind randomized placebo-controlled study demonstrated 3-month efficacy and safety of a novel pediatric-appropriate prolonged-release melatonin (PedPRM) for insomnia in children and adolescents with autism spectrum disorder
Autor:
Nava Zisapel
Publikováno v:
British Journal of Pharmacology. 175:3190-3199
In mammals, a central circadian clock, located in the suprachiasmatic nuclei (SCN) of the hypothalamus, tunes the innate circadian physiological rhythms to the ambient 24 h light-dark cycle to invigorate and optimize the internal temporal order. The
Autor:
Robert L. Findling, Nava Zisapel, John Breddy, Paul Gringras, Beth A. Malow, Athanasios Maras, Tali Nir, Carmen M. Schröder
Publikováno v:
Journal of the American Academy of Child and Adolescent Psychiatry
Objective: A recent 3-month double-blind, placebo-controlled study demonstrated efficacy and safety of pediatric prolonged-release melatonin (PedPRM) for insomnia in children with autism spectrum disorder. This study examined the long-term effects of
Publikováno v:
International Clinical Psychopharmacology
Surveillance studies are useful to evaluate how a new medicinal product performs in everyday treatment and how the patient who takes it feels and functions, thereby determining the benefit/risk ratio of the drug under real-life conditions. Prolonged-